Abstract Index
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
| J | ||
| JAK2 V617F MUTATION IS ASSOCIATED WITH THE LEUKOCYTE COUNT AND BONE MARROW CD34+ CELLS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA | ||
| Moreno M.J., Navarro-Nuñez L., Martinez C., Rivera J., Ferrer F., Ortuño F., Vicente V., Lozano M.L. | ||
| JAK2-V617F IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM | ||
| Lauw M.N., Bus E.B., Van Wulfften Palthe A.F.Y., Homburg C.H., Coppens M., Middeldorp S., Van der Schoot C.E., Koene H.R. | ||
| JOINT RANGE OF MOTION (ROM) MEASUREMENTS IN PATIENTS WITH VON WILLEBRAND DISEASE COMPARED WITH NORMAL SUBJECTS | ||
| Soucie J.M., Forsyth A., Watson C., Wang C., U.D.C. Investigators | ||
| JUNCTIONAL ADHESION MOLECULE A (JAM-A) NEGATIVELY REGULATES AGONIST-INDUCED PLATELET ACTIVATION | ||
| Naik M.U., Stalker T.J., Brass L., Naik U.P. | ||